"Harvard Business Review," well-known columnist Stefan? Tuomu Ke had made this assertion: "In today's world there is a deep-seated problems: the economy is increasingly dependent on service and innovation process is still a product oriented. We have a lot of product development and improvement of the scientific method, but no set of strict and continuous service development process. "This, too, a biomedical industry in Beijing has been working on. R & D services, the way the Chinese biomedical industry Data, biomedical research and development services 80 originated in the early 20th century America. At that time the United States laws and regulations as the continuous improvement of Pharmacy Administration, New Drugs Increasingly strict examination and approval, resulting in the increasing cost of drug development, has also been extended period. In order to survive in the fierce competition and development, system Pharmaceutical companies For new drug development industr y to improve efficiency and reduce costs and risks to consider, some aspects of R & D process outsourcing part or all of the capabilities of external professional organizations or enterprises, thus gave birth to R & D services. With the rapid development of the industry, its services have been divided for the R & D engineering services, R & D services and R & D results service categories, and then covering the whole process of biomedical research. With the United States similar to the biomedical industry in China face the same biggest challenge is to find the most suitable for development of the perfect service system. With the global division of labor continue to refine innovative, new drug development in the field of innovation chain was significantly elongated. In order to achieve the optimal allocation of resources, new drug development chain has been divided into several areas, sub-specialization of different institutions to commence the study, respectively. That is, t he birth of a new drug is no longer as before R & D by a single agency, but rather the result of joint efforts of several professional organizations. Along with this new drug R & D model adjustments and changes, R & D services as a new industry, new drug development has been fully embedded into all aspects of the industry chain, the chain of innovation an integral and support. With this change, the Beijing Municipal Science and Technology Commission from a single enterprise, single-project support, to fully support the "standards-link" of the Industrial Innovation Alliance, a clear mechanism for such a system increasingly innovative strategies and steps, it is Beijing biomedical industry rise to the driving force for change. Based mechanism of institutional innovation ideas, the Beijing Municipal Science and Technology Commission found that the advance of biomedical research and development services is a measure of the degree of national and regional drug created an import ant sign of ability, plays in the innovation chain and support integral role, is also building enterprises as the mainstay of drug development are an important foundation and safeguard. Beijing Municipal Science Committee that "the level of R & D capabilities and service level of development is directly related to Beijing and even the overall level of China's new drug created to enhance." Innovative mechanism in the Beijing Science and Technology Commission under the guidance system of innovative ideas, ideas based mechanism of institutional innovation, conform to industry rules, starting from the market demand to attract and rely on domestic and foreign outstanding service enterprises and R & D agencies formation of bio-technology outsourcing services in China Union (ABO Union), in the areas of the capital development of biological medicine is playing an increasingly important role. "With industry alliance to promote the convergence of resources has become an important pro ducer services development work means. ABO Union, an important task is to form a complete chain services to multinational companies with the whole industry chain and dialogue, and enhance their own competitiveness, participation global division of labor. "Beijing Science and Technology Commission of the ABO The coalition aims to make a case of interpretation. Information, bio-technology outsourcing services in China Alliance (ABO) is now promoting the biomedical industry structure adjustment of China's major strengths. 10 years ago, China's biomedical industry completely rely on the manufacturing sector, and now, in Beijing, Shanghai and other developed areas of biological pharmaceutical industry, the integration of manufacturing and services increasingly apparent trend. In Beijing, biotechnology and new pharmaceutical industry promotion center (BPBC) Zhang Ze, deputy director of Industry appears: "Beijing as the national center of innovation, with leading technology and ri ch resources of clinical resources, has a proprietary technology with a number of R & D services and the relative focus on the Bureau of Pharmaceutical Affairs system, the service sector in the development of pharmaceutical R & D has a unique advantage. Because of this, Beijing will no doubt become the rapid development of China's pharmaceutical R & D service area representatives. "
Website Design & SEO
No comments:
Post a Comment